Fig. 6.
Actuarial risk of developing spent phase of myelofibrosis with splenic metaplasia. The figure indicates the time of diagnosis after the first infusion of 32P. (A) Intention to treat. (B) Main treatment.
Actuarial risk of developing spent phase of myelofibrosis with splenic metaplasia. The figure indicates the time of diagnosis after the first infusion of 32P. (A) Intention to treat. (B) Main treatment.
